<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04996121</url>
  </required_header>
  <id_info>
    <org_study_id>XZP-5955-1001</org_study_id>
    <nct_id>NCT04996121</nct_id>
  </id_info>
  <brief_title>A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>The Safety Tolerability Pharmacokinetic Characteristics and Efficacy of XZP-5955 Tablets in Patients With NTRK or ROS1 Gene Fusion Locally Advanced or Metastatic Solid Tumors in a Single-arm Open-label Multi-center Phase I/II Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuanzhu Biopharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xuanzhu Biopharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase I/II study to examine the safety, tolerability, pharmacokinetics and efficacy of&#xD;
      XZP-5955 tablets in patients with advanced solid tumors harboring NTRK or ROS1 gene fusion&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">June 2027</completion_date>
  <primary_completion_date type="Anticipated">September 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) (Phase I dose escalation)</measure>
    <time_frame>24days following first dose of XZP-5955</time_frame>
    <description>Determine MTD of XZP-5955</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with adverse events (Phase I dose escalation)</measure>
    <time_frame>within 30 days from last dose</time_frame>
    <description>Incidence of AE as assessed by CTCAE 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR) by Blinded Independent Central Review (BICR) (Phase I dose expansion and phase II)</measure>
    <time_frame>2 to 3 years after first dose of XZP-5955</time_frame>
    <description>Per RECIST v1.1 as assessed by BICR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I: Area under the concentration versus time curve of XZP-5955 in plasma (AUC)</measure>
    <time_frame>Pre-dose, up to 72h after drug on Day 1；pre-dose on day 8, day 15 of cycle 1, , pre-dose and up to 12h after drug on day21 of cycle 1;pre-dose on day1 of cycle 2 and 3</time_frame>
    <description>To determine the area under the plasma concentration time curve (AUC) of XZP-5955</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Maximum plasma concentration (Cmax) of XZP-5955</measure>
    <time_frame>Up to 72 hours post dose of Day 1</time_frame>
    <description>To determine the maximum plasma concentration (Cmax) of XZP-5955</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Oral clearance (CL/F) of XZP-5955</measure>
    <time_frame>Pre-dose, up to 72h after drug on Day 1；pre-dose on day 8, day 15 of cycle 1, pre-dose and up to 12h after drug on day21 of cycle 1;pre-dose on day1 of cycle 2 and 3</time_frame>
    <description>To determine the oral clearance (CL/F) of XZP-5955</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate (ORR) (Phase I and Phase II)</measure>
    <time_frame>2 to 3 years after first dose of XZP-5955</time_frame>
    <description>To determine the preliminary objective response rate (ORR) by investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) (Phase I and Phase II)</measure>
    <time_frame>2 to 3 years after first dose of XZP-5955</time_frame>
    <description>To determine the PFS by BICR and investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) (Phase I and Phase II)</measure>
    <time_frame>2 to 3 years after first dose of XZP-5955</time_frame>
    <description>To determine the DOR by BICR and investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) (Phase I and Phase II)</measure>
    <time_frame>2 to 3 years after first dose of XZP-5955</time_frame>
    <description>To determine the DOR by BICR and investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR) (Phase I and Phase II)</measure>
    <time_frame>2 to 3 years after first dose of XZP-5955</time_frame>
    <description>To determine the CBR by BICR and investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR) (Phase I and Phase II)</measure>
    <time_frame>2 to 3 years after first dose of XZP-5955</time_frame>
    <description>To determine the TTR by BICR and investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death of response (DpR) (Phase I and Phase II)</measure>
    <time_frame>2 to 3 years after first dose of XZP-5955</time_frame>
    <description>To determine the DpR by BICR and investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) (Phase I expansion period and Phase II)</measure>
    <time_frame>2 to 3 years after first dose of XZP-5955</time_frame>
    <description>To determine the OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial objective response rate (Phase I expansion period and Phase II)</measure>
    <time_frame>To determine the intracranial ORR</time_frame>
    <description>2 to 3 years after first dose of XZP-5955</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events ((Phase I dose expansion and Phase II)</measure>
    <time_frame>within 30 days from last dose</time_frame>
    <description>Incidence of AE as assessed by CTCAE 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pop PK of XZP-5955 and its metabolite (Phase II)</measure>
    <time_frame>pre-dose, Tmax on Day1, pre-dose on day 8 of cycle 1, pre-dose on day 1 of Cycle 2, Tmax,ss on Day 1 of cycle 2, pre-dose on day 1 of cycle 3</time_frame>
    <description>To determine the PopPK characteristics of XZP-5955</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Locally Advanced or Metastatic Solid Tumors</condition>
  <condition>Locally Advanced or Metastatic Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>XZP-5955 tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XZP-5955 tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XZP-5955 tablets</intervention_name>
    <description>Phase I dose escalation:&#xD;
For each dose cohort, XZP-5955 tablet will be administered orally, single dose for day 1 and then from day 4, administered for continuous cycles of 21 consecutive days for each cycle&#xD;
Phase I dose expansion:&#xD;
XZP-5955 tablet will be administered orally, once daily for continuous cycles of 21 consecutive days for each cycle. Some patients for PK sample collection, the drug will be administered single dose for day 1, then from day 4, administered for continuous cycles of 21 consecutive days for each cycle&#xD;
Phase II:&#xD;
XZP-5955 tablet will be administered orally, once daily for continuous cycles of 21 consecutive days for each cycle</description>
    <arm_group_label>XZP-5955 tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects aged ≥18 years old;&#xD;
&#xD;
          2. Phase I dose escalation period: Histologically or cytologically confirmed diagnosis of&#xD;
             locally advanced, or metastatic solid tumor, assessed by investigator that no standard&#xD;
             therapy exists, or the tumor has relapsed, progressed or was nonresponsive to&#xD;
             available therapies, or intolerance, or not suitable to standard therapy at current&#xD;
             stage. Priority will be given to patients who have previously documented NTRK or ROS1&#xD;
             gene fusion confirmed by the central laboratory; Phase I dose expansion and Phase II:&#xD;
             Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic&#xD;
             solid tumor, patients can provide a written report of pathological diagnosis of NTRK&#xD;
             or ROS1 positive tested by qualified laboratory;&#xD;
&#xD;
          3. Phase I dose expansion cohort 1 and Phase II cohort 1: locally advanced, or metastatic&#xD;
             solid tumor with NTRK gene fusion Phase I dose expansion cohort 2 and Phase II cohort&#xD;
             2： locally advanced, or metastatic NSCLC with ROS1 gene fusion that has progressed to&#xD;
             crizotinib and other therapies or was intolerance to crizotinib Phase I dose expansion&#xD;
             cohort 3: locally advanced, or metastatic NSCLC with ROS1 gene fusion who have not&#xD;
             previously received crizotinib or other therapy.&#xD;
&#xD;
          4. phase I dose escalation: at least 1 measurable target lesion according to RECIST&#xD;
             version 1.1 Phase I dose expansion and Phase II: at least 1 measurable target lesion&#xD;
             according to RECIST version 1.1 (Tumor lesions treated with prior radiation or other&#xD;
             local treatment are considered measurable if they show definite progression)&#xD;
&#xD;
          5. ECOG PS 0-1&#xD;
&#xD;
          6. Life expectancy ≥ 3 months.&#xD;
&#xD;
          7. Adequate organ function:&#xD;
&#xD;
             Baseline laboratory values fulfilling the following requirements: Absolute neutrophils&#xD;
             count (ANC) ≥1.5 × 109/L; Platelets (PLTs) ≥75 × 109/L; Hemoglobin ≥ 85g/L; Serum&#xD;
             creatinine≤ 1.5 × ULN， or creatinine clearance ≥50 mL/min/1.73m2(only when serum&#xD;
             creatinine&gt;1.5 × ULN); Total serum bilirubin ≤1.5 × ULN; Liver transaminases (AST/ALT)&#xD;
             ≤ 2.5 × ULN，≤3× ULN if liver metastases are present or liver cancer patients;&#xD;
             Activated Partial Thromboplastin Time≤1.5× ULN；International Normalized Ratio&#xD;
             (INR)≤1.5× ULN；&#xD;
&#xD;
          8. Eligible patients (male and female) who are fertile must agree to at least use a&#xD;
             reliable contraceptive method with partner during the trial and within 90 days from&#xD;
             the last dose; Women of childbearing age must have a negative serum pregnancy test&#xD;
             within 7 days before the first dose of the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received anti-tumor therapy such as chemotherapy, radiotherapy, biotherapy, endocrine&#xD;
             therapy, immunotherapy or other therapy within 4 weeks prior to the first dose of the&#xD;
             investigational drug except the following:&#xD;
&#xD;
             Nitroso ureas or mitomycin C within 6 weeks before the first dose of the drug; Oral&#xD;
             fluorouracil and small molecule targeted drugs within 2 weeks prior to the first dose&#xD;
             of drug or within 5 half life (whichever is longer);&#xD;
&#xD;
          2. Received other unmarketed investigational drugs or treatments within 4 weeks prior to&#xD;
             the first dose of the investigational drug;&#xD;
&#xD;
          3. Major organ surgery (except biopsy) or significant trauma within 4 weeks prior to&#xD;
             first dose of the investigational drug or required elective surgery during the trial;&#xD;
&#xD;
          4. Adverse reactions to previous antitumor therapy have not recovered to NCI CTCAE 5.0 ≤&#xD;
             grade 1 (except for alopecia, grade 2 peripheral neurotoxicity, stable hypothyroidism&#xD;
             after hormone replacement therapy, etc.);&#xD;
&#xD;
          5. Inability to swallow drug, or a condition that the investigator judged to severely&#xD;
             affect gastrointestinal absorption (eg:Chronic Diarrhea, intestinal obstruction,&#xD;
             etc.);&#xD;
&#xD;
          6. Cerebral or meningeal metastases with clinical symptoms. The below patients were&#xD;
             allowed to be included: those who were asymptomatic, stable, and did not require&#xD;
             steroid treatment for more than 4 weeks prior to the start of study treatment (if the&#xD;
             cerebral metastases had undergone radiotherapy or/and surgery, radiotherapy and&#xD;
             surgery should be at least 1 month prior to the first dose) ;&#xD;
&#xD;
          7. Known active infections and currently need intravenous anti-infective therapy;&#xD;
&#xD;
          8. History of immune deficiencies, including positive HIV antibody tests;&#xD;
&#xD;
          9. Active Hepatitis B (HBsAg and/or HBcAb positive with HBV-DNA &gt; 500IU/ml) or hepatitis&#xD;
             c virus infection (positive test results of anti-HCV with positive HCV-RNA );&#xD;
&#xD;
         10. Known interstitial lung disease (except for radioactive pulmonary fibrosis that does&#xD;
             not require steroid therapy);&#xD;
&#xD;
         11. History of serious cardiovascular disease;&#xD;
&#xD;
         12. Pregnant or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuankai Shi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cuilan Xiao</last_name>
    <phone>+86-13699167610</phone>
    <email>xiaocuilan@xuanzhubio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yuankai Shi, Doctor</last_name>
      <phone>+86-13701251865</phone>
      <email>syuankaipumc@126.com</email>
    </contact>
    <investigator>
      <last_name>Yuankai Shi, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 6, 2021</study_first_submitted>
  <study_first_submitted_qc>August 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>XZP-5955</keyword>
  <keyword>Safety, tolerability, pharmacokinetics and efficacy</keyword>
  <keyword>Solid tumors with NTRK or ROS1 gene fusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

